AVITA Medical Inc
avitamedical.comWhat Do They Do?
Sells RECELL skin-cell harvesting devices and wound-care products to hospitals, other treatment centers, and distributors.
10-K for FY2025, filed Feb 12, 2026Our current commercial portfolio includes RECELL® (“RECELL”), and two complementary wound care products, PermeaDerm® and Cohealyx™, which…View ↗
RECELL remains the cornerstone of our business; however, beginning in 2024 we evolved AVITA Medical into a multi-product acute wound care…View ↗
RECELL is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient’s own skin cells, called…View ↗
The sale of RECELL EOU, RPK and mini RPK (collectively, the “RPKs”), PermeaDerm, and Cohealyx products to hospitals, other treatment…View ↗
How Do They Make Money?
Hospitals, treatment centers and distributors buy RECELL products, PermeaDerm and Cohealyx; product-sale revenue is counted when the goods are sold. AVITA also earns lease revenue for the reusable RECELL GO device.
10-K for FY2025, filed Feb 12, 2026The sale of RECELL EOU, RPK and mini RPK (collectively, the “RPKs”), PermeaDerm, and Cohealyx products to hospitals, other treatment…View ↗
Lease revenue for the RPD.View ↗
The Company recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the…View ↗
The RECELL GO and RECELL GO mini devices consist of single-use RPKs and a durable AC powered device, the RPD. The Company enters into…View ↗
$71.6M
-
10-K for FY2025, filed Feb 12, 2026
$71.6M ↗
Who Are Their Customers?
Hospitals and other treatment centers buy AVITA’s wound-care products, while international sales go through third-party distributors.
10-K for FY2025, filed Feb 12, 2026The sale of RECELL EOU, RPK and mini RPK (collectively, the “RPKs”), PermeaDerm, and Cohealyx products to hospitals, other treatment…View ↗
Outside the U.S., RECELL has received regulatory approvals or registrations in multiple markets, including Australia, Europe, and Japan. In…View ↗
For international markets, the Company exclusively partners with third-party distributors (currently, COSMOTEC in Japan, PolyMedics…View ↗
Do Revenues Turn Into Profits?
No. It lost $48.6M in FY2025.
10-K for FY2025, filed Feb 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$7.7MView ↗
- ▼ −23% (Loss)
- vs −$9.9M in Q2 FY2025
-
Aug 11, 2026
AVITA amended its PermeaDerm agreements with Stedical
The amendment changes revenue shares, gives AVITA a right of first offer and refusal on certain international territories, and allows Stedical to sell in some U.S. markets.
Sources
8-K, filed Aug 11, 2026
On August 5, 2026, the Company and Stedical Scientific, Inc. (“Stedical”) entered into a Global Amendment of their existing distribution…View ↗
-
Aug 6, 2026
AVITA raised its 2026 revenue guidance
The 2026 revenue range rose to $86 million to $89 million from $80 million to $85 million; AVITA also expects cash flow breakeven in the fourth quarter of 2026.
Sources
8-K, filed Aug 6, 2026
Based on the Company’s second quarter performance, AVITA Medical is increasing its full-year 2026 revenue guidance to be in the range of…View ↗
-
May 1, 2026
AVITA appointed Cary Vance as CEO
Jan Stern Reed was also appointed Chair of the Board.
Sources
8-K, filed May 1, 2026
On April 29, 2026, the Board of Directors (the “Board”) of AVITA Medical, Inc (the "Company") appointed Cary Vance as President and Chief…View ↗
Growing. Revenue grew 2.4x in 4 years, from $29.2M in FY2020 to $71.6M in FY2025, about 25% a year.
A broader wound-care portfolio
The older report centered on RECELL and planned expansion into additional indications. The latest report describes a multi-product acute wound-care platform that also includes Cohealyx and PermeaDerm.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 12, 2026
Vitiligo commercialization
The older report planned commercializing RECELL for vitiligo after approvals and reimbursement; the latest report says AVITA has paused further commercial investment because reimbursement remains limited and uncertain.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 12, 2026Commercialize the RECELL System in the U.S. for use in treatment of vitiligo following approval of our pending PMA application, which was…View ↗
Loading...
